189 related articles for article (PubMed ID: 35277559)
21.
Hu Z; Qu S
Front Immunol; 2021; 12():683572. PubMed ID: 34267752
[TBL] [Abstract][Full Text] [Related]
22. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas.
Yi L; Fan X; Li J; Yuan F; Zhao J; Nistér M; Yang X
Aging (Albany NY); 2021 Jan; 13(3):3645-3660. PubMed ID: 33493139
[TBL] [Abstract][Full Text] [Related]
23. IL13RA2 is overexpressed in malignant gliomas and related to clinical outcome of patients.
Zeng J; Zhang J; Yang YZ; Wang F; Jiang H; Chen HD; Wu HY; Sai K; Hu WM
Am J Transl Res; 2020; 12(8):4702-4714. PubMed ID: 32913543
[TBL] [Abstract][Full Text] [Related]
24. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
25. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
26. A novel DNA damage and repair-related gene signature to improve predictive capacity of overall survival for patients with gliomas.
Li X; Wang Y; Wu W; Xiang J; Wang M; Yu H
J Cell Mol Med; 2022 Jul; 26(13):3736-3750. PubMed ID: 35615996
[TBL] [Abstract][Full Text] [Related]
27. CD96, a new immune checkpoint, correlates with immune profile and clinical outcome of glioma.
Liu F; Huang J; He F; Ma X; Fan F; Meng M; Zhuo Y; Zhang L
Sci Rep; 2020 Jul; 10(1):10768. PubMed ID: 32612110
[TBL] [Abstract][Full Text] [Related]
28. Molecular-genetic and clinicopathological prognostic factors in patients with gliomas showing total 1p19q loss: gain of chromosome 19p and histological grade III negatively correlate with patient's prognosis.
Hayashi S; Kitamura Y; Hirose Y; Yoshida K; Sasaki H
J Neurooncol; 2017 Mar; 132(1):119-126. PubMed ID: 28025770
[TBL] [Abstract][Full Text] [Related]
29. Identification of integrative molecular and clinical profiles of Fibrinogen-like protein 2 in gliomas using 1323 samples.
Song Z; Wang Y; Du Y; Zhang Z; Yuan Y
Int Immunopharmacol; 2020 Nov; 88():106894. PubMed ID: 32858440
[TBL] [Abstract][Full Text] [Related]
30. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
Zhang ZY; Chan AK; Ding XJ; Qin ZY; Hong CS; Chen LC; Zhang X; Zhao FP; Wang Y; Wang Y; Zhou LF; Zhuang Z; Ng HK; Yan H; Yao Y; Mao Y
Oncotarget; 2015 Sep; 6(28):24871-83. PubMed ID: 26314843
[TBL] [Abstract][Full Text] [Related]
31. Tumor-associated macrophages related signature in glioma.
Wang LJ; Xue Y; Lou Y
Aging (Albany NY); 2022 Mar; 14(6):2720-2735. PubMed ID: 35332109
[TBL] [Abstract][Full Text] [Related]
32. Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas.
Haque W; Thong E; Andrabi S; Verma V; Brian Butler E; Teh BS
J Clin Neurosci; 2021 Mar; 85():115-121. PubMed ID: 33581781
[TBL] [Abstract][Full Text] [Related]
33. Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system.
Figarella-Branger D; Bouvier C; de Paula AM; Mokhtari K; Colin C; Loundou A; Chinot O; Metellus P
J Neurooncol; 2012 Nov; 110(2):205-13. PubMed ID: 22890969
[TBL] [Abstract][Full Text] [Related]
34. Systemic and local immunosuppression in glioblastoma and its prognostic significance.
Stepanenko AA; Sosnovtseva AO; Valikhov MP; Chernysheva AA; Abramova OV; Pavlov KA; Chekhonin VP
Front Immunol; 2024; 15():1326753. PubMed ID: 38481999
[TBL] [Abstract][Full Text] [Related]
35. PDIA3 correlates with clinical malignant features and immune signature in human gliomas.
Zhang H; Zhou Y; Cheng Q; Dai Z; Wang Z; Liu F; Fan F; Cui B; Cao H
Aging (Albany NY); 2020 Aug; 12(15):15392-15413. PubMed ID: 32687065
[TBL] [Abstract][Full Text] [Related]
36. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
37. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
[TBL] [Abstract][Full Text] [Related]
38. PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas.
Zhang H; He J; Dai Z; Wang Z; Liang X; He F; Xia Z; Feng S; Cao H; Zhang L; Cheng Q
Front Immunol; 2021; 12():628966. PubMed ID: 33664747
[TBL] [Abstract][Full Text] [Related]
39. ANXA2 is correlated with the molecular features and clinical prognosis of glioma, and acts as a potential marker of immunosuppression.
Ma K; Chen X; Liu W; Yang Y; Chen S; Sun J; Ma C; Wang T; Yang J
Sci Rep; 2021 Oct; 11(1):20839. PubMed ID: 34675316
[TBL] [Abstract][Full Text] [Related]
40. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]